Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration
Science · 13.11.2025 · 390 (6774)
DOI: 10.1126/science.adq1177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 13.11.2025. Verfasst von Yulin Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Receptors, Formyl Peptide, Multiple Sclerosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
Multiple sclerosis (MS) progresses through brain region–specific inflammation and degeneration, with poorly defined mechanisms. In individuals with MS, we identified increased expression of formyl peptide receptor 1 (FPR1) in central nervous system (CNS)–resident microglia and CNS-infiltrating macrophages. Blood amounts of N -formylated peptides, which are endogenous agonists of FPR1, correlated with disease progression in patients with MS. In MS mouse models, signaling through FPR1 promoted microglial mitochondrial dysfunction, causing axonal loss and apoptosis. FPR1-expressing microglia sustained the clonal expansion of myelin-reactive CD4 + T cells in the CNS. A CNS-penetrating small molecule FPR1 antagonist, T0080, mitigated autoimmune responses and axonal degeneration. Our study identifies FPR1 signaling as a potential mechanism for MS progression and suggests antagonizing FPR1 as a therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Neurology, Tiantan Neuroimaging Center of Excellence, China National Clinical Research Canter for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrueck Center for Molecular Medine, Berlin, Germany.
- Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
- Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, UK.
ORCID-Profile: Yulin Li, Zhiguo Li, Pei Zheng, Shuzhen Guan, Yan Li, Nan Yao, Xueyu Zhang, Jing Jing, Chotima Böttcher, Hans-Gustaf Ljunggren, Friedemann Paul, Luc Van Kaer, Alexei Verkhratsky, Fu-Dong Shi
Zitieren
APA
Li, Y., Li, Z., Zheng, P., Guan, S., Li, Y., Yao, N., Qi, Z., Zhang, X., Su, L., Jing, J., Wu, S., Zhao, X., Wang, M., Böttcher, C., Ljunggren, H. G., Paul, F., Van Kaer, L., Verkhratsky, A., & Shi, F. D. (2025). Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration. Science, 390(6774). https://doi.org/10.1126/science.adq1177
Vancouver
Li Y, Li Z, Zheng P, Guan S, Li Y, Yao N, et al. Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration. Science. 2025;390(6774). doi:10.1126/science.adq1177
BibTeX
@article{Li2025,
author = {Li, Yulin and Li, Zhiguo and Zheng, Pei and Guan, Shuzhen and Li, Yan and Yao, Nan and Qi, Zhihui and Zhang, Xueyu and Su, Lei and Jing, Jing and Wu, Siting and Zhao, Xue and Wang, Meng and Böttcher, Chotima and Ljunggren, Hans-Gustaf and Paul, Friedemann and Van Kaer, Luc and Verkhratsky, Alexei and Shi, Fu-Dong},
title = {Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration},
journal = {Science},
year = {2025},
volume = {390},
number = {6774},
doi = {10.1126/science.adq1177}
}
EUVIMED